Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Other Non-Current Assets (2019 - 2025)

Historic Other Non-Current Assets for Pulmonx (LUNG) over the last 7 years, with Q3 2025 value amounting to $1.5 million.

  • Pulmonx's Other Non-Current Assets rose 48798.45% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year increase of 48798.45%. This contributed to the annual value of $1.1 million for FY2024, which is 9221.66% up from last year.
  • Pulmonx's Other Non-Current Assets amounted to $1.5 million in Q3 2025, which was up 48798.45% from $1.6 million recorded in Q2 2025.
  • Pulmonx's Other Non-Current Assets' 5-year high stood at $1.6 million during Q2 2025, with a 5-year trough of $231000.0 in Q1 2021.
  • Moreover, its 5-year median value for Other Non-Current Assets was $257000.0 (2024), whereas its average is $568052.6.
  • Its Other Non-Current Assets has fluctuated over the past 5 years, first plummeted by 4484.98% in 2024, then skyrocketed by 56949.15% in 2025.
  • Pulmonx's Other Non-Current Assets (Quarter) stood at $731000.0 in 2021, then dropped by 27.63% to $529000.0 in 2022, then rose by 11.72% to $591000.0 in 2023, then surged by 92.22% to $1.1 million in 2024, then soared by 33.54% to $1.5 million in 2025.
  • Its Other Non-Current Assets stands at $1.5 million for Q3 2025, versus $1.6 million for Q2 2025 and $1.6 million for Q1 2025.